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Background: While step counter use has become popular among type 2 diabetes (T2D) patients, its effectiveness
in increasing physical activity (PA) and improving glycemic control has been poorly defined. The aim of this
meta-analysis of randomized controlled trials (RCTs) was to evaluate the association of step counter use with PA
and glycemic control in T2D patients.
Methods: Articles were identified by searches of PubMed, Web of Science and Cochrane Library from January 1994
to June 2013. RCTs in the English language were included, if they had assessed the effectiveness of step counters
as motivating and monitoring tools in T2D patients, with reported changes in steps per day (steps/d) or
glycosylated hemoglobin A1c (HbA1c), or both. Data were independently collected by 2 authors and overall
estimates were made by a random-effects model.
Results: Of the 551 articles retrieved, 11 RCTs were included. Step counter use significantly increased PA by 1,822
steps/d (7 studies, 861 participants; 95% confidence interval (CI): 751 to 2,894 steps/d) in patients with T2D. Step
counter use with a PA goal showed a bigger increase in PA (weighted mean difference (WMD) 3,200 steps/d, 95%
CI: 2,053 to 4,347 steps/d) than without (WMD 598 steps/d, 95% CI: −65 to 1,260 steps/d). Further subgroup analysis
suggested step counter use with a self-set PA goal (WMD 2,816 steps/d, 95% CI: 1,288 to 4,344 steps/d) made no
difference in increasing PA from a 10,000 steps/d goal (WMD 3,820 steps/d, 95% CI: 2,702 to 4,938 steps/d).
However, no significant HbA1c change was observed by step counter use (10 studies, 1,423 participants; WMD
0.02%, 95% CI: −0.08% to 0.13%), either with (WMD 0.04%, 95% CI: −0.21% to 0.30%) or without a PA goal
(WMD 0.01%, 95% CI: −0.10% to 0.13%).
Conclusions: Step counter use is associated with a significant increase in PA in patients with T2D. However,
evidence regarding its effect in improving glycemic control remains insufficient.
Trial registration: PROSPERO CRD42013005236
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Physical activity (PA) is a cornerstone of type 2 diabetes
(T2D) management [1]. Increased PA is strongly associ-
ated with improvement in insulin sensitivity, glycemic
control, weight reduction, and related microvascular and
macrovascular complications among T2D [2-6]. How-
ever, most patients with T2D do not become regularly
active or get adequate PA [7,8], with poor self-efficacy,* Correspondence: sunzilin1963@126.com
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tributing factors [9,10].
Lifestyle interventions to change behavior and promote
self-efficacy have been very successful in increasing PA
[11-13] and improving health outcomes [11,14,15]. As one
of the intervention strategies, the step counter (for example,
pedometer or accelerometer) has become popular [15]; it is
smart, inexpensive and mainly designed to count the num-
ber of steps walked daily. The systematic review by Bravata
et al. [16] pointed out the effectiveness of step counter use
in increasing PA and the importance of a PA goal; however,
analysis was carried out not only on the general population,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Their conclusion on the benefit of step counter use in
increasing PA in patients with T2D is less robust. Moreover,
the contradictory findings in other studies [17,18] raise con-
cerns about its effectiveness as a motivating and monitoring
tool in promoting PA in T2D patients. The joint position
statement from the American College of Sports Medicine
and the American Diabetes Association (2010) recommends
patients with T2D to walk more often with a goal in mind
(for example, 10,000 steps per day (steps/d)) [1]. The
evidence for this recommendation is drawn largely from
Bravata et al. [16]. It remains questionable whether this
encouragement correlates with a significant improvement
in PA in patients with T2D.
Well-documented evidence suggests that step counter
use decreases blood pressure, lipid profiles and improves
the quality of life in patients with T2D [19]; while studies
on step counter use for improving glycemic control in pa-
tients with T2D give conflicting results [15,19]. Although
Bravata et al. [16] argued that step counter use was not
associated with a decreased fasting serum glucose concen-
tration, its association with chronic glycemic control, as
assessed by glycosylated hemoglobin A1c (HbA1c), remains
unknown, which is considered to be the mainstay of
T2D management.
Thus, it is of great interest to conduct a meta-analysis
of RCTs to evaluate the association of step counter use
with PA as measured by steps/d, and glycemic control as
represented by HbA1c; and to determine the association
between PA goal-setting and improvement in PA and
glycemic control in patients with T2D.
Methods
Data sources and search strategies
The following electronic databases were searched from
January 1994 to June 2013: PubMed, Web of Science and
Cochrane Library. In consultation with a medical research
librarian, the MeSH term “diabetes mellitus” and text words
“pedomet*”, “acceleromet*” or “step counter” were com-
bined for search in PubMed, a search strategy that was
adapted for other databases (see Additional file 1). The
related references of all included articles were collected
and hand-searched to make sure no suitable and rele-
vant studies were missed. This meta-analysis is re-
ported with reference to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [20], and adhered to a registered protocol
(PROSPERO CRD42013005236; see Additional file 2).
Study selection
Inclusion criteria were defined according to the “PICOS”
Principle: participants, interventions, comparisons, out-
comes and study design. Participants were outpatients who
had T2D. Inpatient diabetes, type 1 diabetes, gestationaldiabetes and pre-diabetes, such as impaired glucose toler-
ance and fasting glucose, were excluded. Interventions that
used step counters as motivating and monitoring tools for
increasing PA were included, while those used for moni-
toring walking speed (for example, steps per minute) or
solely for assessing the effects of a lifestyle program on PA
were excluded. Interventions were compared to a control
arm given the usual care intervention or with step counters
used only for counting steps.
RCTs in the English language were eligible for inclu-
sion, if they had included more than 5 participants,
and reported changes in steps/d or HbA1c, or both
(the primary outcome). Studies were excluded if the
data of interest were insufficient or could not be obtained
from the authors. Since HbA1c reflects the average blood
glucose concentration during the previous 8 to 12 weeks,
analyses were limited to step counter use lasting for at
least 8 weeks [21].
Data extraction and quality assessment
Preliminary selection was based on titles and abstracts
of retrieved articles. Abstracts without adequate informa-
tion for inclusion or exclusion criteria were retrieved for
full-text evaluation. Two authors (SHQ and XC) selected
and independently assessed the studies. Discrepancies were
resolved by discussion or consensus.
For each of the relevant articles, extracted data included
details of the study population (age and sample size), inter-
vention characteristics (intervention duration, whether a
diary was used and a PA goal was set), outcome variables
(steps/d or HbA1c, or both), adherence to step counter
use and dropout rates. Data extraction was conducted
by XC and checked by XC for accuracy or missing infor-
mation. Quality was assessed independently by 2 authors
(SHQ and XC) using the Cochrane Collaboration’s ‘Risk
of Bias’ Tool [22], which includes random sequence gene-
ration, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete
outcome data and selective reporting. Each item was judged
as low, unclear or high risk of bias, according to criteria in
the Cochrane Handbook (see Additional file 3) [23].
Data synthesis and analysis
For trials that reported the standard error (SE) of a mean,
the standard deviation (SD) was obtained by multiplying
by the square root of the sample size from the appropriate
arm. If the 95% confidence interval (CI) was shown instead
of an SD, the SD was calculated by dividing the length of
the CI by 3.92, and multiplying by the square-root of the
sample size (n), provided that n was more than 60. For
some trials that compared multiple step counter interven-
tions with a single control group, an approach was applied
that combined the multiple intervention arms into a single
one to overcome the unit-of-analysis error. If trials had an
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were used in the primary analyses. Both final values and
change scores from baseline of steps/d and HbA1c were
entered in the same meta-analysis, as suggested in the
Cochrane Handbook for Systematic Reviews [23]. Data
from intention-to-treat (ITT) or per-protocol analyses
were entered when available in included studies.
The analyses used Stata Software (Version 11.0, College
Station, TX, USA). Summary estimates were analyzed
with a random-effects model, which coincides with a
fixed-effects model when no heterogeneity is presented
[23]. The Cochran Q test was used to assess heterogeneity
among the studies, with a threshold P-value of 0.1 being
considered statistically significant. The degree of incon-
sistency among trials was estimated by the I2 statistic,
where an I2 value greater than 50% was considered sub-
stantially heterogenic. Heterogeneity was explored using
3 strategies: first, sensitivity analyses were conducted by
removing each study individually to check whether it
could explain heterogeneity; second, univariate meta-
regression analyses helped to assess whether the clinical
or methodological variables influenced the outcome esti-
mates; and third, subgroup analyses were performed based
on meta-regression analyses and pre-specified relevant
study characteristics. Publication bias was detected and
assessed by Begg's test and Egger's test.
Results
Study characteristics
The databases yielded 551 potentially relevant articles.
After careful screening for inclusion and exclusion, 11
RCTs met all the criteria for inclusion in the meta-
analysis (Figure 1). Of these, 7 trials reported data of
steps/d and 10 trials gave results for HbA1c. Of the trials
measuring PA, 3 used the Yamax DigiWalker SW200
pedometer (Yamax Corpo, Tokyo, Japan) [24-26], 1 used
the Omron HJ-720ITC pedometer (Omron Healthcare, Inc.;
Bannockburn, Illinois, America) [27], with the remaining 3
not giving details [28-30]. Of the trials measuring HbA1c,
1 used the Adams procedure [24], 2 used the DCA 2000
(details not provided) [27,31], 1 used the Tosoh A1c 2.2
Plus Glycohemoglobin Analyzer (Tosoh Medics, Inc.;
Foster City, California, America) [26], and the others
were unknown [18,25,29,30,32,33]. All 11 trials had
been carried out in developed countries: 3 in Belgium, 2
in Britain, 1 in Norway, 2 in America, 1 in Canada and
2 in Australia. The characteristics of these citations are
summarized in Table 1.
Four RCTs gave data on adherence to the step counter
intervention, with all adherence rates more than 75%.
Dropout rates were less than 16% in all but 4 of the 11
studies (Table 1). No major adverse effects related to
step counter use, such as musculoskeletal injury, shin
soreness or hypoglycemia, were reported. A minor adversecondition was poor health that was not associated with
the intervention [30].
Among the 11 included studies, 54.5% (6/11) provided
adequate random sequence generation, with 2 trials using a
computer generator [24,32], 2 using blocked randomization
[27,30], 1 using stratified (gender and age) randomization
[25], and 1 using numbered sealed envelopes [29]; 54.5%
(6/11) reported proper allocation concealment, with 4
trials using sealed envelopes [24,25,27,29] and 2 using
central allocation [30,32]. All studies had blinded as-
sessment of outcomes, and described losses to follow-up
and exclusions; 45.5% (5/11) carried out ITT analyses
[24,25,28,29,32], whereas 54.5% (6/11) used per-protocol
analyses [18,26,27,30,31,33]. The risk of bias assessment
for each study is listed in Table 2.
Effect on PA
Seven studies (861 participants) comparing step counter
use (504 participants) versus control (357 participants)
showed that step counter use was associated with a
significant increase in PA by 1,822 steps/d (95% CI: 751 to
2,894 steps/d; Figure 2). However, the result was statistically
heterogeneous (P <0.001, I2 = 85.9%).
In meta-regression analyses, PA-goal setting partially
explained the heterogeneity between these studies, whereas
sample size, intervention duration, diary use and study
quality could not (see Additional file 4). Subgroup ana-
lyses suggested step counter use along with a PA goal
(4 studies, 147 participants) significantly increased PA by
3,200 steps/d (95% CI: 2,053 to 4,347 steps/d; P for hetero-
geneity = 0.170, I2 = 40.3%) compared with the control. Step
counter use without a PA goal (3 studies, 357 participants)
did not significantly increase the PA (weighted mean
difference (WMD) 598 steps/d, 95% CI: −65 to 1,260
steps/d; P for heterogeneity = 0.067, I2 = 63.1%) compared
with the control (Figure 2). Further subgroup analysis
found no significant difference (P = 0.300) between step
counter use with a 10,000 steps/d goal (WMD 3,820
steps/d, 95% CI: 2,702 to 4,938 steps/d) or a self-set PA goal
(WMD 2,816 steps/d, 95% CI: 1,288 to 4,344 steps/d). Step
diary use was also associated with a significant increase in
PA (WMD 2,186 steps/d, 95% CI: 962 to 3,411 steps/d);
whereas without diary, there was no significant increase
(WMD 115 steps/d, 95% CI: −721 to 951 steps/d). When
studies were individually removed from this meta-analysis,
heterogeneity and WMDs remained unchanged.
No evidence of significant publication bias in the analysis
of step counter use was detected by Begg's test (P = 0.368)
or Egger's test (P = 0.147).
Effect on glycemic control
Ten studies (1,423 participants) were included in the
meta-analysis. The overall, pooled data suggested a
non-significant association between step counter use and
n = 551): 
PubMed (n = 151), 
Potentially relevant articles identified (
Web of Science (n = 332), 
Cochrane Library (n = 68)
Exclude duplicted articles (n = 198)
Full-text articles screened for eligibility (n = 54)
Exclude articles on review of full text (n = 43)
Not randomized controlled trials (n = 11)
Poster or author reply (n = 7)
No available data (n = 4)
Step counter not used for motivation (n = 16)
Not type 2 diabetes (n = 2)
Others (n = 3)
Articles included in the meta-analysis (n = 11)
Exclude articles on review of title and abstract 
(n = 299)
Remained articles after excludng duplicates (n = 353)
Number of additional articles by hand-searching
(n = 0)
Full-text articles assessed for eligibility (n = 54)
Figure 1 Flow diagram of articles identified.
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compared with the control (Figure 3). No statistical signifi-
cant heterogeneity was found among the studies (P = 0.589,
I2 <1%). Neither step counter use with a PA goal (5 studies,
133 participants) nor without (5 studies, 646 participants)
was associated with any significant improvement in HbA1c
(WMD 0.04%, 95% CI: −0.21% to 0.30% and WMD 0.01%,
95% CI: −0.10% to 0.13%, respectively) compared with
the control (Figure 3). When each study was removed
individually from the meta-analysis to evaluate possible
individual effects on the summary estimates, heterogeneity
and WMDs remained unchanged.
Minor publication bias with under-representation of
articles reporting negative effect in HbA1c was noted,
as indicated by Begg's test (P = 0.107) and Egger's test
(P = 0.144).
Discussion
Summary of the main findings
The results of the meta-analyses show that in patients
with T2D, step counter use is associated with a significant
increase in PA - a magnitude of 1,822 steps/d. The
meta-analyses also show that with a PA goal, step counter
use is associated with greater benefit in increasing PA(WMD 3,200 steps/d, 95% CI: 2,053 to 4,347 steps/d)
than without it (WMD 598 steps/d, 95% CI: −65 to
1,260 steps/d), indicating that the use of a PA goal is
an important predictor of increased PA. Additionally,
step counter use with a self-set PA goal makes no differ-
ence in increasing PA from a 10,000 step/d goal. However,
the analyses do not reveal a conclusive glycemic control
benefit of step counter use in T2D patients, regardless of a
PA goal or not.
Interpretation
In accordance with our main results, Bravata et al. [16]
noted that step counter use was associated with a significant
increase of 2,491 steps/d (95% CI: 1,098 to 3,885 steps/d),
and setting a steps/d goal (for example, 10,000 steps/d) was
an important predictor of increased PA. However, it sounds
impractical to recommend patients with T2D to take 10,000
steps/d in the initial period, since the descriptive meta-
analysis by Bohannon [34] showed the number of
pedometer-assessed steps taken per day by adults aged
65 years or older was much lower than 10,000, and the fact
that diabetic patients always show impaired tolerance of PA
[35,36]. Considering that 10,000 steps/d goal made no
difference from a self-set goal in increasing PA according
Table 1 Characteristics of the studies included in the meta-analyses
Source Age mean
(SD), ya
Intervention and control description Co-intervention Duration, mo Adherence,% Dropouts,%
De Greef et al.
2011-1b [24]
68.3 (8.2) Intervention: a pedometer-based PA program: received
a pedometer, set personal goal, instructed to increase
self-efficacy and received physical advice.
Diary use;
Self-set goal
3 Not stated 2.3
66.0 (11.1) Control: received usual care 8.3
De Greef et al.
2010 [25]
61.3 (6.3) Intervention: a cognitive-behavioral program: received
a pedometer; instructed to increase self-efficacy and set




61.3 (6.9) Control: received usual care 9.5
Tudor-Locke
et al. 2004 [26]
52.8 (5.7) Intervention: a First Step program: received a
pedometer, instructed for self-monitoring and




52.5 (4.8) Control: only received postcards for thanks 23.3
Piette et al.
2011e [27]
55.1 ( 9.4) Intervention: received a telephone-delivered cognitive
behavioral therapy, including a pedometer-based PA
program, and instructed to progress toward cognitive
behavioral therapy goals.
Diary use 9 Not stated 15.7
56.0 (10.9) Control: received an enhanced usual care 12.6
De Greef et al.
2011-2 [28]
62 (9) (total) Intervention: a pedometer-based behavioral
modification program with telephone support:
received a pedometer, and seven calls for




3 Not stated 3.3
Control: received usual care 6.3
Kirk et al.
2009c, e [29]
62.1 (10.2) Intervention: received a pedometer, a 12-week walking
plan and strategies to increase self-efficacy, given
physical consultation and follow-up phone calls.
No diary or
goal use
6 Not stated 9.1





61.8 (11.8) Intervention: received a pedometer, PA guidelines
and stage-based, print materials for behavior change.
Diary use 12 80 24.9
61.0 (11.7) Control: received standard PA education materials 10.6
Engel et al.
2006 [31]
60.5 (7.34) Intervention: received a pedometer and coaching
(which included education, behavior-change strategies




3 Not stated 12 (total)
64 (6.76) Control: received coaching only, instructed to increase
self-efficacy, and set goals on time spent walking per day
Bjørgaas et al.
2008 [18]
56.4 (11.0) Intervention: received a pedometer, encouraged to
increase steps/d and set goals for increasing PA.
Diary use;
Increase steps/d
6 Not stated 28
61.2 (9.7) Control: encouraged to increase the average daily




60.0 (9.7) Intervention: received intensive diet intervention, a
pedometer, and motivating literature; instructed to
walk more for five weeks, and then maintain.
Diary use 6 90 1.2
60.1 (10.2) Control: received intensive diet intervention 0.4
Diedrich et al.
2010e [33]
56.7 (13.6) Intervention: attended DSMEP, and received a




3 Not stated 38 (total)
54.9 (9.8) Control: attended DSMEP
DSMEP, Diabetes Self-Management Education Program; PA, physical activity; steps/d, steps per day; SD, standard deviation; mo, month.
aIn studies with 2 interventions, age data represent combined mean (SD) of each intervention group.
bTwo intervention group differed in delivery strategy (one was by individual consultation, the other one was by group counseling).
cTwo intervention group differed in delivery strategy (one was by person, the other one was in written form).
dTwo intervention group differed in telephone counselling (one was with, the other one was not).
eGoals were not specified in those studies.
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Table 2 Bias assessment of each study












De Greef et al. 2011-1 [24] Low Low Low Low Low Low
De Greef et al. 2010 [25] Low Low Low Low Low Low
Tudor-Locke et al. 2004 [26] Unclear Unclear Low Low High Low
Piette et al. 2011 [27] Low Low Low Low High Low
De Greef et al. 2011-2 [28] Unclear Unclear Low Low Low Low
Kirk et al. 2009 [29] Low Low Low Low Low Low
Plotnikoff et al. 2013 [30] Low Low Low Low High Low
Engel et al. 2006 [31] Unclear Unclear Low Low High Low
Bjørgaas et al. 2008 [18] Unclear Unclear Low Low High Low
Andrews et al. 2011 [32] Low Low Low Low Low Low
Diedrich et al. 2010 [33] Unclear Unclear Low Low High Low
Summary assessments of the risk of bias for each RCT within studies:
Low risk of bias, low risk of bias for all key domains; unclear risk of bias, unclear risk of bias for one or more key domains; high risk of bias, high risk of bias for
one or more key domains.
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tients with T2D to initially set their own steps/d goals,
and gradually increase to a recommended higher level
(for example, 10,000 steps/d) [1,37]. This study also showed
that step diary use was another key motivational factor for
increasing PA, which corresponds with the Bravata et al.
review [16] and an observational study [38].Sample size
Source Intervention Control WM
With a PA goal
De Greef et al. 2011-2 60 32 3,820 (
De Greef et al. 2010 20 21 4,063 (
De Greef et al. 2011-1 43 24 1,598 (
Tudor-Locke et al. 2004 24 23 3,501 (
Subgroup estimates (P < 0.001) 3,200 (
Without a PA goal
Kirk et al. 2009 82 33 115 (-7
Piette et al. 2011 145 146 1,185 (
Plotniko et al. 2013 130 78 359 (-3
Subgroup estimates (P = 0.077) 598 (-6
Overall estimates (P = 0.001) 1,822 (
Figure 2 Forest plot of RCTs investigating step counter use in PA (ste
participants completing the trials. Summary estimates were analyzed with a
RCTs, randomized controlled trials; steps/d, steps per day; T2D, type 2 diabeA cross-sectional study indicated that each SD increment
in steps/d (2,609) is associated with a 0.21% lower HbA1c,
after adjusting some anthropometric parameters in patients
with T2D [39]. Another randomized and stratified study in-
dicated that step counter use increased daily walking, and
improved glycemic control by decreasing HbA1c 0.26% in











-3,500 0 3,500 7,000
Favors Control Favors Intervention
ps/d) in T2D patients. The sample size represents the number of
random-effects model. CI, confidence interval; PA, physical activity;
tes; WMD, weighted mean difference.
Sample size
Source Intervention Control WMD (95% CI) %, Weight
With a PA goal 
De Greef et al. 2010 20 21 -0.60 (-1.34, 0.14) 1.99
De Greef et al. 2011-1 43 24 -0.01 (-0.44, 0.42) 5.71
Tudor-Locke et al. 2004 24 23 0.00 (-1.03, 1.03) 1.02
Bjørgaas et al. 2008 22 24 0.08 (-0.55. 0.71) 2.74
Engel et al. 2006 24 30 0.27 (-0.11, 0.65) 7.63
Subgroup estimates (P = 0.742 ) 0.04 (-0.21, 0.30) 19.08
Without a PA goal
Andrews et al. 2011 246 248 0.03 (-0.15, 0.21) 32.61
Kirk et al. 2009 98 34 -0.30 (-0.87, 0.27) 3.32
Piette et al. 2011 145 145 0.00 (-0.40, 0.40) 6.63
Plotniko et al. 2013 141 79 0.07 (-0.11, 0.25) 34.41
Diedrich et al. 2010 16 16 -0.30 (-0.82, 0.22) 3.94
Subgroup estimates (P = 0.800) 0.01 (-0.10, 0.13) 80.92
Overall estimates (P = 0.673) 0.02 (-0.08, 0.13) 100,00
0-1 -0.5 0.5 1
Favors Control Favors Intervention
Figure 3 Forest plot of RCTs investigating step counter use in HbA1c (%) in T2D patients. The sample size represents the number of
participants completing the trials. Summary estimates were analyzed with a random-effects model. CI, confidence interval; HbA1c, glycosylated
hemoglobin A1c; PA, physical activity; RCTs, randomized controlled trials; T2D, type 2 diabetes; WMD, weighted mean difference.
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counter use could improve glycemic control. There are a
number of possible explanations. First, and probably the
most important, the baseline HbA1c levels in the included
patients with T2D were relatively well controlled (their
mean baseline concentrations of HbA1c ranged from 6.64%
to 8.0%). To some extent, step counter use can be adopted
as an effective strategy for maintaining glycemic control.
Second, information on anti-diabetic drug treatment (for
example, insulin or sulphonylurea) and dietary intake fol-
lowing step counter intervention was in general poorly re-
corded, except one study that gave full details on diet [32].
The studies that were included therefore failed to clarify
whether the lack of glycemic benefit of step counter use
could be attributed to changes in drug dosage or diet. Fi-
nally, since the exercise intensity predicted post-intervention
HbA1c change to a larger extent than exercise volume in
patients with T2D [41], inadequate reporting of walking in-
tensity made it difficult to assess the effectiveness of step
counter use in improving glycemic control.
Strengths and limitations
The strength of this study includes large sample sizes
and well-designed RCTs, and is to date the mostcomprehensive meta-analysis to assess the effectiveness
of step counter use in patients with T2D. However, there
are several limitations: first, although not indicated by
the formal statistical analysis, possibilities remain of
publication bias considering that only studies published
in the English language were included and 3 electronic
databases were searched. Second, high heterogeneity
seen in the studies in PA was identified in the meta-
analyses and it could not be fully explained by a single
related factor. The relatively small number of studies
may have contributed to the heterogeneity. Furthermore,
high risk of bias due to incomplete outcome data treated
with per-protocol analyses could contribute to this het-
erogeneity. Therefore, better designed RCTs with guide-
lines for reporting data are urgently needed [42]. Third,
the step counters used to measure the steps/d were dif-
ferent or not specified, and the method for determining
HbA1c concentration was largely unknown. These could
increase the risk of clinical heterogeneity. Fourth, since
step counter intervention in all studies was combined
with more than one component (for example, step goal,
phone call or consultation), it is difficult to clarify the in-
dependent contribution of each component. Fifth, this
study is limited to the use of HbA1c to analyze glycemic
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portant marker [43]; however, none of these included tri-
als was examined. Future research should also focus on
the glycemic excursion, with regard to glycemic control,
when using step counters in patients with T2D. Finally,
this study failed to assess the association between step
counter use and other cardiometabolic risk factors, such
as blood pressure, lipids and lipoproteins.
Conclusions
In conclusion, step counter use leads to a significant
increase in PA in patients with T2D, which is comparable
to that given in the previous report [16]. The use of a PA
goal is an important predictor of increased PA, and it seems
initially better to use a self-set PA goal. However, evidence
regarding the effect of step counter use in improving gly-
cemic control remains insufficient in this meta-analysis.
More research with better detailed PA goals, and focusing
more on medication use, walking intensity and glycemic
excursion, is warranted.
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